GLP-1s are basically appetite’s off-switch: suddenly you’re “full” after three bites. Congrats on the smaller meals and ...

One of the biggest risk factors for prediabetes is weight gain. Over the past several decades, rates of obesity have risen ...

GLP-1 receptor agonists like semaglutide and tirzepatide have redefined what’s possible in the treatment of obesity and metabolic syndrome. These medications have shown remarkable results in appetite ...

These will help you build a supportive foundation for the body.

Phenomix's MyPhenome test continues to demonstrate predictive accuracy in identifying which patients are most likely to respond to GLP-1 therapies such as semaglutide. Studies presented at Obesity ...

Psoriasis and psoriatic arthritis (PsA) are chronic, immune-mediated inflammatory diseases associated with several shared common comorbidities, of which obesity is one of the most prevalent. A complex ...

Kristen Fischer has written for numerous health publications, hospitals, and medical companies, and is a member of the Association of Health Care Journalists. Nick Blackmer is a librarian, ...

The discussion surrounding GLP-1 medications needs to change to one that emphasizes science-based research and compassion.

Metabolic surgery was associated with lower all-cause mortality and a lower risk for major adverse cardiac events than GLP-1 receptor agonists (RAs), based on data from a new study of more than 3000 ...

Oprah Winfrey has spoken openly about using GLP-1s to lose weight in the last few years ...

The MarketWatch News Department was not involved in the creation of this content. Studies presented at Obesity Week 2025 validate the test's ability to predict weight-loss response to GLP-1 drugs like ...